Abstract
Background: The most recurrent and considered second most frequent cause of cancer-related deaths worldwide in women is the breast cancer. The key to diagnosis is early prediction and a curable stage but still treatment remains a great clinical challenge.
Origin of the Problem: A number of studies have been carried out for the treatment of breast cancer which includes the targeted therapies and increased survival rates in women. Essential PI3K/mTOR signaling pathway activation has been observed in most breast cancers. The cell growth and tumor development in such cases involve phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) complex intracellular pathway. Hypothesis: Through preclinical and clinical trials, it has been observed that there are a number of other inhibitors of PI3K/Akt/mTOR pathway, which either alone or in combination with cytotoxic agents can be used for endocrine therapies. Conclusion: Structure and regulation/deregulation of mTOR provides a greater insight into the action mechanism. Also, through this review, one could easily scan first and second generation inhibitors for PI3K/Akt/mTOR pathway besides targeted therapies for breast cancer and the precise role of mTOR.Keywords: PI3K/Akt/mTOR, breast cancer, cell proliferation, intracellular, cytotoxic, therapy.
Current Pharmaceutical Design
Title:PI3K/Akt/mTOR Intracellular Pathway and Breast Cancer: Factors, Mechanism and Regulation
Volume: 23 Issue: 11
Author(s): Var Ruchi Sharma, Girish Kumar Gupta, A. K. Sharma, Navneet Batra, Daljit K. Sharma, Amit Joshi and Anil K. Sharma*
Affiliation:
- Department of Biotechnology, M.M. University, Mullana-Ambala -133207, Haryana,India
Keywords: PI3K/Akt/mTOR, breast cancer, cell proliferation, intracellular, cytotoxic, therapy.
Abstract: Background: The most recurrent and considered second most frequent cause of cancer-related deaths worldwide in women is the breast cancer. The key to diagnosis is early prediction and a curable stage but still treatment remains a great clinical challenge.
Origin of the Problem: A number of studies have been carried out for the treatment of breast cancer which includes the targeted therapies and increased survival rates in women. Essential PI3K/mTOR signaling pathway activation has been observed in most breast cancers. The cell growth and tumor development in such cases involve phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) complex intracellular pathway. Hypothesis: Through preclinical and clinical trials, it has been observed that there are a number of other inhibitors of PI3K/Akt/mTOR pathway, which either alone or in combination with cytotoxic agents can be used for endocrine therapies. Conclusion: Structure and regulation/deregulation of mTOR provides a greater insight into the action mechanism. Also, through this review, one could easily scan first and second generation inhibitors for PI3K/Akt/mTOR pathway besides targeted therapies for breast cancer and the precise role of mTOR.Export Options
About this article
Cite this article as:
Sharma Ruchi Var, Gupta Kumar Girish, Sharma K. A., Batra Navneet, Sharma K. Daljit, Joshi Amit and Sharma K. Anil*, PI3K/Akt/mTOR Intracellular Pathway and Breast Cancer: Factors, Mechanism and Regulation, Current Pharmaceutical Design 2017; 23 (11) . https://dx.doi.org/10.2174/1381612823666161116125218
DOI https://dx.doi.org/10.2174/1381612823666161116125218 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Activation of p53 in Cancer Cells
Current Pharmaceutical Design The Pro-Survival Function of Akt Kinase can be Overridden or Altered to Contribute to Induction of Apoptosis
Current Cancer Drug Targets Autoimmune Channelopathies of the Nervous System
Current Neuropharmacology Updating the Chemistry and Biology of Cannabinoid CB2 Receptor – Specific Inverse Agonists
Current Topics in Medicinal Chemistry Identification of Novel Breast Cancer Genes based on Gene Expression Profiles and PPI Data
Current Proteomics Development of Taxol and Other Endophyte Produced Anti-Cancer Agents
Recent Patents on Anti-Cancer Drug Discovery Sodium Dependent Multivitamin Transporter (SMVT): A Potential Target for Drug Delivery
Current Drug Targets Homologation: A Versatile Molecular Modification Strategy to Drug Discovery
Current Topics in Medicinal Chemistry Anabolic Androgenic Steroids Abuse and Liver Toxicity
Mini-Reviews in Medicinal Chemistry Toxicity and Relative Biological Effectiveness of Alpha Emitting Radioimmunoconjugates
Current Radiopharmaceuticals Snake Venom Phospholipases A2: A New Class of Antitumor Agents
Protein & Peptide Letters Circulating Cellular Players in Vascular Calcification
Current Pharmaceutical Design Natural Bioactive Compounds, Vegetal Extracts and Modern Pharmaceutical Formulations: New Insights into the Anti-Cancer Mechanism of Action
Anti-Cancer Agents in Medicinal Chemistry Design and Synthesis of Mannich bases as Benzimidazole Derivatives as Analgesic Agents
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Current Status and Future Directions of Nanoparticulate Strategy for Cancer Immunotherapy
Current Drug Metabolism Translational Research of Optical Molecular Imaging for Personalized Medicine
Current Molecular Medicine Role of Cytomegalovirus in Salivary Gland Tumors: An Unfolded Mystery
Recent Patents on Biomarkers Glycogen Synthase Kinase-3 (GSK-3) Inhibitors for the Treatment of Alzheimers Disease
Current Pharmaceutical Design Approaches for Developing Novel Microtubule Targeting Agents (MTAs) for Therapeutic Exploitation
Current Pharmaceutical Design G Protein-Coupled Receptors in Regulation of Body Weight
CNS & Neurological Disorders - Drug Targets